Sugi Predict

Sugi Predict / Compounds / SCHEMBL2060122

SCHEMBL2060122

SCHEMBL2060122

COc1cc2c(c(OC)c1)C(=O)OC2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.71
▸ GAA P10253 2/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.71
▸ CYP3A4 P08684 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ ACHE P22303 1/20 0.53
▸ PDE5A O76074 1/20 0.49
▸ PDE4A P27815 1/20 0.49
▸ PDE1A P54750 1/20 0.49
▸ PDE1B Q01064 1/20 0.49
▸ PDE4B Q07343 1/20 0.49
▸ PDE4C Q08493 1/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ PDE3B Q13370 1/20 0.49
▸ PDE1C Q14123 1/20 0.49
▸ PDE3A Q14432 1/20 0.49
▸ MAOB P27338 1/20 0.48
▸ MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434781 1.00 KDM4E (0.71) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL2060277 0.83 KDM4E (1.00) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL30321447 0.82 KDM4E (0.57) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL20231727 0.81 CYP3A4 (0.53) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL31496832 0.81 CYP3A4 (0.53) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL286593 0.77 KDM4E (0.49) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL349476 0.76 ALDH1A1 (0.50) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL286469 0.76 IMPDH2 (0.48) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL286641 0.76 KDM4E (0.48) KDM4EGAASMN1; SMN2CYP3A4LMNA
SCHEMBL286768 0.74 KDM4E (0.49) KDM4EGAASMN1; SMN2CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109055233-B Fungus for producing dimethoxy isobenzofuran-1-one and method for preparing dimethoxy isobenzofuran-1-one by fungus 黑龙江大学 2021-08-17 — — CN claimed
CN-113912577-B Rockwell intermediate, rockwell and its derivative, and preparation and application 深圳湾实验室 2023-12-29 — — CN disclosed
CN-113912577-A Lockmilanol intermediate, Lockmilanol and derivatives thereof, preparation and application 深圳湾实验室 2022-01-11 — — CN disclosed
CN-109055233-B Fungus for producing dimethoxy isobenzofuran-1-one and method for preparing dimethoxy isobenzofuran-1-one by fungus 黑龙江大学 2021-08-17 — — CN disclosed
US-10144746-B2 Bridged bicyclic kallikrein inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2018-12-04 — — US disclosed
US-20180194780-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2018-07-12 — — US disclosed
US-9815853-B2 Bridged bicyclic kallikrein inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-11-14 — — US disclosed
WO-2016201052-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2016-12-15 — — WO disclosed
US-20160362427-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2016-12-15 — — US disclosed
EP-1883415-B1 WATER INSOLUBLE HELICHRYSUM EXTRACT, PROCESS FOR PREPARING THE SAME AND USES THEREOF ABOCA SPA SOCIETA AGRICOLA (IT) 2012-05-16 — — EP disclosed
US-8147878-B2 Water insoluble helychrisum extract, process for preparing the same and uses thereof ABOCA S.P.A. SOCIETA' AGRICOLA (IT) 2012-04-03 — — US disclosed
US-20110250301-A9 WATER INSOLUBLE HELYCHRISUM EXTRACT, PROCESS FOR PREPARING THE SAME AND USES THEREOF ABOCA S.P.A. SOCIETA' AGRICOLA (IT) 2011-10-13 — — US disclosed
US-20100227012-A1 WATER INSOLUBLE HELYCHRISUM EXTRACT, PROCESS FOR PREPARING THE SAME AND USES THEREOF ABOCA S.P.A. SOCIETA' AGRICOLA (IT) 2010-09-09 — — US disclosed
EP-1266887-B1 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-08-17 — — EP disclosed
US-6627650-B2 An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. LES LABORATOIRES SERVIER (FR) 2003-09-30 — — US disclosed
US-20030125369-A1 Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent LES LABORATOIRES SERVIER (FR) 2003-07-03 — — US disclosed
EP-1266887-A2 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2002-12-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10144746-B2 Bridged bicyclic kallikrein inhibitors KLKB1, KLK1, KLK2 KDM4E 927/4885GAA 1733/4885SMN1; SMN2 4494/4885
US-20160362427-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS KLKB1, KLK1, KLK2 KDM4E 927/4885GAA 1733/4885SMN1; SMN2 4494/4885
US-20180194780-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS KLKB1, KLK1, KLK2 KDM4E 927/4885GAA 1733/4885SMN1; SMN2 4494/4885
US-20030125369-A1 Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent IDO1, IDO2, AHR KDM4E 2363/4885GAA 4583/4885SMN1; SMN2 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.